ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action

  • Stephen P. Arnerić
  • Anthony W. Bannon
  • Jorge D. Brioni
  • Clark A. Briggs
  • Michael W. Decker
  • Mark W. Holladay
  • Kennan C. Marsh
  • Diana Donnelly-Roberts
  • James P. Sullivan
  • Michael Williams
  • Jerry J. Buccafusco
Part of the Advances in Alzheimer Disease Therapy book series (AADT)

Abstract

Recent evidence suggests the existence of a diversity of neuronal nicotinic acetylcholine receptor (nAChRs) subtypes with a wide distribution in brain, that each subtype may be involved in mediating specific functions/behaviors, and that these subtypes have a defined pharmacology that may be selectively targeted (Arnerić et al., 1995a). The pharmacologic diversity of neuronal nAChR subtypes suggests the possibility of developing selective compounds which would have more favorable side-effect profiles than existing agents which generally exhibit low selectivity. This broader class of agents, collectively called cholinergic channel modulators (ChCMs) selectively activate some subtypes of nAChRs (i.e. Cholinergic Channel Activators, ChCAs) or inhibit the function of other subtypes (Cholinergic Channel Inhibitors, ChCIs).

Keywords

Toxicity Dopamine Lactate Nicotine Serotonin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnerić SP, Holladay MW, and Sullivan JP (1996): Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer’s disease. Exp. Opin. Invest. Drugs 5(1): 79–100.CrossRefGoogle Scholar
  2. Arnerić SP, Sullivan JP and Williams M (1995a): Neuronal nicotinic acetylcholine receptors: novel targets for CNS therapeutics. In: Psychopharmacology: 4th Generation of Progress, Bloom F.E. and Kupfer DJ, eds., New York, Raven Press; pp. 94–110.Google Scholar
  3. Arnerić SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Decker MW, Brioni JD, Marsh KC, and Rodrigues AD (1995b): Preclinical pharmacology of ABT-418: A prototypical cholinergic channel activator for the potential treatment of Alzheimer’s disease CNS Drug Rev. 1: 1–26.CrossRefGoogle Scholar
  4. Donnelly-Roberts DL, Xue I, Arneric SP and Sullivan JP (1996): In vitro neuroprotective properties of the novel cholinergic channel activator (CA), ABT-418. Brain Res. (In press).Google Scholar
  5. Lin N-H., Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Sullivan JP, Williams M, Arnerić SP, and Holladay MW (1996): Structure-Activity Studies on ABT-089: An orally bioavailable 3-pyridyl ether cholinergic channel modulator with cognitive enhancing properties and improved safely profile. J Med Chem. (In press).Google Scholar
  6. Newhouse P, Potter A, and Corwin J (1996): Acute administration of the cholinergic channel activator ABT-418 improves learning in Alzheimer’s disease. SRNT 2nd Annual Conference, Washington, D.C., March 16.Google Scholar

Copyright information

© Birkhäuser Boston 1997

Authors and Affiliations

  • Stephen P. Arnerić
    • 1
  • Anthony W. Bannon
    • 1
  • Jorge D. Brioni
    • 1
  • Clark A. Briggs
    • 1
  • Michael W. Decker
    • 1
  • Mark W. Holladay
    • 1
  • Kennan C. Marsh
    • 1
  • Diana Donnelly-Roberts
    • 1
  • James P. Sullivan
    • 1
  • Michael Williams
    • 1
  • Jerry J. Buccafusco
    • 2
  1. 1.Neuroscience, D-47W, Pharmaceutical Products DivisionAbbott LaboratoriesAbbott ParkUSA
  2. 2.Department of Pharmacology and ToxicologyMedical College of Georgia AugustaUSA

Personalised recommendations